Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients

Authors not listed

Fondazione EMN Italy Onlus · 2008

Abstract

This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR (and CR) in newly diagnosed elderly MM patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
Anonymous. (2008). A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients. <em>Fondazione EMN Italy Onlus</em>. https://clinicaltrials.gov/study/NCT01160107
Vancouver
Anonymous. A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients. Fondazione EMN Italy Onlus. 2008.
BibTeX
@misc{anon2008AMulti, title = {A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients}, author = {Anonymous}, journal = {Fondazione EMN Italy Onlus}, year = {2008}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings